Product Code: IRTNTR6305
About Opioid-induced Constipation
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs.
Technavio's analysts forecast the global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs.
On the basis of the mechanism of action of drugs, the market is grouped into the following categories:
- Peripherally Acting Mu-opioid Receptor Antagonist
- Locally Acting Chloride Channel Activator
- Others
On the basis of the route of administration of drugs, the market is grouped into the following categories:
On the basis of the dosage form of drugs, the market is grouped into the following categories:
Technavio's report, Global Opioid-induced Constipation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Key Vendors
- AstraZeneca
- Takeda Pharmaceutical
- Valeant Pharmaceuticals International
Other Prominent Vendors
- Abbott
- Bayer
- Boehringer Ingelheim
- C.B. Fleet
- Cosmo Pharmaceuticals
- Daewoong
- Daiichi Sankyo
- GlaxoSmithKline
- Ironwood Pharmaceuticals
- Johnson & Johnson
- Merck
- Mundipharma
- Nektar Therapeutics
- Pfizer
- Progenics Pharmaceuticals
- Shionogi
- SLA Pharma
- Sucampo
- Synergy Pharmaceuticals
- Theravance
Market Driver
- Unmet Medical Needs
- For a full, detailed list, view our report
Market Challenge
- Availability of OTC and Off-label Drugs
- For a full, detailed list, view our report
Market Trend
- Shift to Targeted Therapy
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
- 03.1. Market Overview
- 03.2. Product Offerings
04. Product Profiles
- 04.1.1. Amitiza
- 04.1.2. Movantik/Moventig
- 04.1.3. Relistor
05. Market Research Methodology
- 05.1. Market Research Process
- 05.2. Research Methodology
06. Introduction
07. Disease Overview
- 07.1. Understanding Opioid-induced Constipation
- 07.2. Symptoms
- 07.3. Pathophysiology
- 07.4. Epidemiology
- 07.5. Diagnosis
- 07.5.1. Patient History
- 07.5.2. Bristol Stool Form Scale
- 07.5.3. Physical Examination
- 07.5.4. Laboratory Tests
- 07.5.5. Further Investigational Procedures
- 07.6. Treatment and Management
- 07.6.1. Pharmacotherapeutic Approach
- 07.6.2. Non-pharmacotherapeutic Approach
08. Pipeline Portfolio
- 08.1. Key Information of Pipeline Molecules
- 08.1.1. Naldemedine
- 08.1.2. Linaclotide
- 08.1.3. Axelopran/TD-1211
- 08.1.4. SP-333
- 08.1.5. Oral Naloxone
09. Market Landscape
- 09.1. Market Overview
- 09.2. Market Size and Forecast
- 09.3. Five Forces Analysis
10. Market Segmentation by Mechanism of Action
- 10.1. Peripherally Acting Mu-opioid Receptor Antagonist
- 10.2. Locally Acting Chloride Channel Activator
- 10.3. Others
11. Market Segmentation by Route of Administration
- 11.1. Oral
- 11.2. Parenteral
12. Market Segmentation by Dosage Form
13. Geographical Segmentation
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
- 21.1. Competitive Scenario
- 21.1.1. Key News
- 21.1.2. Mergers and Acquisitions
- 21.2. Market Share Analysis 2014
- 21.2.1. Takeda Pharmaceutical
- 21.2.2. Valeant Pharmaceuticals International
- 21.2.3. AstraZeneca
- 21.3. Other and Future Prominent Vendors
22. Key Vendor Analysis
- 22.1. AstraZeneca plc
- 22.1.1. Key Facts
- 22.1.2. Business Overview
- 22.1.3. Business Segmentation by Revenue 2013
- 22.1.4. Business Segmentation by Revenue 2011-2013
- 22.1.5. Sales by Geography
- 22.1.6. Business Strategy
- 22.1.7. Key Developments
- 22.1.8. SWOT Analysis
- 22.2. Takeda Pharmaceuticals
- 22.2.1. Key Facts
- 22.2.2. Business Overview
- 22.2.3. Business Segmentation by Revenue 2013
- 22.2.4. Business Segmentation by Revenue 2013
- 22.2.5. Geographical Segmentation by Revenue 2013
- 22.2.6. Business Strategy
- 22.2.7. Recent Developments
- 22.2.8. SWOT Analysis
- 22.3. Valeant Pharmaceuticals International
- 22.3.1. Key Facts
- 22.3.2. Business Overview
- 22.3.3. Business Segmentation by Revenue 2013
- 22.3.4. Business Segmentation by Revenue 2012 and 2013
- 22.3.5. Sales by Geography
- 22.3.6. Business Strategy
- 22.3.7. Key Developments
- 22.3.8. SWOT Analysis
23. Other Reports in this Series
List of Exhibits
- Exhibit 1: Market Research Methodology
- Exhibit 2: Pipeline Drugs: Opioid-induced Constipation
- Exhibit 3: Snapshot of Global Opioid-induced Constipation Market
- Exhibit 4: Global Opioid-induced Constipation Market 2014-2019 ($ millions)
- Exhibit 5: Segmentation of Global Opioid-induced Constipation Market by Mechanism of Action
- Exhibit 6: Segmentation of Global Opioid-induced Constipation Market by Route of Administration
- Exhibit 7: Segmentation of Global Opioid-induced Constipation Market by Dosage Form
- Exhibit 8: Segmentation of Global Opioid-induced Constipation Market by Geography 2014
- Exhibit 9: Drivers of Global Opioid-induced Constipation Market
- Exhibit 10: Challenges in the Global Opioid-induced Constipation Market
- Exhibit 11: Trends of Global Opioid-induced Constipation Market
- Exhibit 12: Takeda Pharmaceuticals: Key Takeaways
- Exhibit 13: Valeant Pharmaceuticals International: Key Takeaways
- Exhibit 14: AstraZeneca: Key Takeaways
- Exhibit 15: AstraZeneca plc: Business Segmentation by Revenue 2013
- Exhibit 16: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
- Exhibit 17: AstraZeneca plc: Sales by Geography 2013
- Exhibit 18: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
- Exhibit 19: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
- Exhibit 20: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
- Exhibit 21: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2013
- Exhibit 22: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
- Exhibit 23: Valeant Pharmaceuticals International: Sales by Geography 2013
